World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.

Slides:



Advertisements
Similar presentations
Current Status and Benefits of Therapy for Chronic Hepatitis C Virus (HCV) Fuad AM Hasan Department Of Medicine Faculty of Medicine Kuwait University.
Advertisements

Advances in the Treatment of Chronic Hepatitis C Gregory T Everson, MD Professor of Medicine Director of Hepatology University of Colorado Denver.
BORDERNETwork Training on HIV and HBV Co-Infections Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A.
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
Hepatitis C In Alaska’s Department of Corrections
Global Hepatitis C Guidelines 2014: recommendations for a public health approach Gottfried Hirnschall.
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
Washington D.C., USA, July 2012www.aids2012.org HCV genotype and HBV co-infection associate with HCV clearance in HIV- positive subjects Yuan Dong,
Managing Hepatitis C: An Unprecedented Correctional Healthcare Challenge ASCA/CCHA meeting Phoenix, AZ RADM Newton E. Kendig Assistant Director/Medical.
HEPATITIS 2014 BC. CHRONIC HEPATITIS B THE PROBLEM 350,000,000 PEOPLE HAVE IT IT IS TRANSMITTED MOTHER TO CHILD WHERE IT IS ENDEMIC IT CAN BE TRANSMITTED.
Treating Hepatitis C in Methadone Patients: With Planning, it Works! Patricia Perkins, MS, MPH Independent Healthcare Consultant Community Advisory Board.
World Hepatitis Day 2013, 29 th July Establishing a framework for better data collection and surveillance of Hepatitis in South Africa N. Prabdial-Sing.
Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.
RCGP training online: new training in short bites Danny Morris, Expert Lead RCGP Hepatitis B and C Part 1.
Overview of Hepatitis B, C, and D Epidemiology in Eastern Europe and the Newly Independent States Michael O. Favorov MD, Ph.D., D.Sc. CDC Central Asia.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2012.
Triglycerides,LDL cholesterol and HOMA score predict the virological response in HIV/HCV co-infected patients treated with Pegylated interferon alpha 2a.
Olivia Chang, MPH Research and Program Manager Pangaea Global AIDS
Pennsylvania: The State of HCV 2015
Susan L. Uprichard, PhD Director of Hepatology Research Loyola University Medical Center Department of Medicine Section of Hepatology HepNet 2013 HCV Virology.
UKCHIC Richard Gilson on behalf of the Hepatitis Subgroup Progress update July 2010 UK CHIC.
Hepatitis C: Perspective on Drug Development Issues Debra Birnkrant, M.D. Director, Division of Antiviral Products FDA Antiviral Drugs Advisory Committee.
Evidence for optimizing highly active antiretroviral treatment (HAART) in Kenya Dr. Washingtone Ochieng CNHR RCDG Fellow returning from Harvard University,
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C Edward J. Gane, M.D., Catherine A. Stedman, M.B., Ch.B. New Engl J Med 2013;
Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:
Henry Masur, MD Bethesda, Maryland
R2. 임형석 / Pf. 김병호. I NTRODUCTION Chronic hepatitis C infection 130~150 million worldwide 7 genotypes genotype 1 predominates(about 70% in USA): most difficult.
Date of download: 9/17/2016 From: The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions Ann Intern Med. 2014;161(3):
Role of Ministry of Health and Medical Education in management and control of Hepatitis C 2016/07/13.
Phase 3 Treatment-Naïve and Treatment-Experienced
Where Are We on the Path to Elimination of Chronic Hepatitis C?
Interim Analysis of a 3-Year Follow-up Study of NS5A and NS3 Resistance-Associated Variants After Treatment With Grazoprevir-Containing Regimens in Patients.
Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;
Hepatitis C Incidence and Prevalence in the U.S.
Impact of Syndemics on People Living with HIV/AIDS in San Francisco
Lesson 3: The HCV Care Continuum
DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?
Building a Data Driven HCV Screening and Linkage-to-Care Program
Talking to Patients About HCV Treatment
Lesson 4: Preventing HCV Reinfection
HCV. The Spectrum of Hepatitis C Virus Infection: From Acute Infection to End-Stage Liver Disease.
Chronic Hepatitis C Virus Infection
Managing Women Living With HIV Infection
Starting Strong: Initial Evaluation of the Patient With HCV
Chronic Kidney Disease in HIV Infection: An Urban Epidemic
Hepatitis C Screening Best Practices Jenitza Serrano-Feliciano M.D
HCV: Who Should We Screen and Why?
The Aging Liver in the Aging HIV and HCV Patients
Best Practices in Screening and Linkage to Care in Hepatitis C Virus
Tiffany G. Harris, PhD, MS Director of Strategic Information
More Than Treatment.
HCV Screening.
Evaluation of the Patient With HCV Infection
What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?
Engaging and Educating the Multidisciplinary Healthcare Team in HCV Care.
Treatment with the second-generation HCV protease inhibitor BI results in high and consistent SVR rates: Results from SILEN-C1 in HCV genotype-1.
HCV Protease Inhibitors in Clinical Practice
Virological tools to diagnose and monitor hepatitis C virus infection
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
2018 Postgraduate Research Symposium: Exploring opportunities
Impact of metabolic risk factors on HCC
Hepatitis C: After the Diagnosis
HCV Protease Inhibitors in Clinical Practice
New HCV therapies on the horizon
Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection  Ira M. Jacobson, Gary L. Davis, Hashem El–Serag, Francesco.
Volume 68, Issue 4, Pages (April 2018)
What Does the Future Hold and What Will It Mean for Patients?
Epidemiology of socially significant infectious diseases (TB, HIV-infection, viral hepatitis C and B) in Russia Olga Nechaeva Expert of the Expert Group.
Core Competency 1: Epidemiologic Background of HIV/HCV Co-infection in the United States Lesson 2: Morbidity and Mortality in HCV Co-infected People Living.
Lesson 3: The HCV Care Continuum
Presentation transcript:

Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV

World Epidemiology

HCV Epidemiology

HCV Subtype Distribution: A Mosaic of Overlapping Sub-Epidemics

HIV-1 Subtypes Worldwide

U.S. Epidemiology

HCV and HIV in the US

HIV/HCV in the U.S.: Epidemiological Overlap

Prevalence of HCV Ab by Demographic Characteristics 1999-2002 NHANES

Relative Importance of Risk Factors for Remote and Recent HCV Infection

Testing and Care

Current Recs for HCV Testing

U.S.: New HIV Infections / Year

HCV infection in the U.S.

CDC Medical Monitoring Project: HIV Update

Virology

Viral Genetic Diversity

Life Cycle of HIV

HCV and HIV Polymerases: Similar Structure and Function

HCV and HIV Proteases

Virology: Summary

Natural History

HIV and HCV: Much in Common

HCV: Natural History

Natural History of HIV Infection

Age-Adjusted HCV Mortality: 1995-2005

Treatment

Assessing Virologic Response in HCV Therapy

HIV Therapy: 1987-1996

HCV Protease Inhibitors

Independent Predictors of Sustained Virologic Response (Logistic Regression)

HIV Drug Approval: 1987 - 2012

ART: 1997-2006

HIV Drug Approval: 1987 - 2012

HIV Drug-Resistance Testing

HIV Cure (N=1)

HCV and HIV: Treatment Issues

HCV + HIV: Healthcare Team

HCV and HIV: Summary

Acknowledgments

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.